Impax Laboratories Wins FDA Tentative Approval for Generic BPH Drug
Impax Laboratories has confirmed that the FDA has granted tentative approval of the company's abbreviated new drug application for generic version of Flomax 0.4mg capsules.
Boehringer Ingelheim Pharmaceuticals markets Flomax for the functional symptoms of benign prostatic hyperplasia.
Impax Laboratories is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products.
Comments